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Abstract
Glucose transporter 4 (GLUT4) is a principal glucose transporter in response to insulin, and impaired translocation or
decreased expression of GLUT4 is believed to be one of the major pathological features of type 2 diabetes mellitus (T2DM).
Therefore, induction of GLUT4 translocation or/and expression is a promising strategy for anti-T2DM drug discovery. Here
we report that the natural product (+)-Rutamarin (Rut) functions as an efficient dual inducer on both insulin-induced GLUT4
translocation and expression. Rut-treated 3T3-L1 adipocytes exhibit efficiently enhanced insulin-induced glucose uptake,
while diet-induced obese (DIO) mice based assays further confirm the Rut-induced improvement of glucose homeostasis
and insulin sensitivity in vivo. Subsequent investigation of Rut acting targets indicates that as a specific protein tyrosine
phosphatase 1B (PTP1B) inhibitor Rut induces basal GLUT4 translocation to some extent and largely enhances insulin-
induced GLUT4 translocation through PI3 kinase-AKT/PKB pathway, while as an agonist of retinoid X receptor a (RXRa), Rut
potently increases GLUT4 expression. Furthermore, by using molecular modeling and crystallographic approaches, the
possible binding modes of Rut to these two targets have been also determined at atomic levels. All our results have thus
highlighted the potential of Rut as both a valuable lead compound for anti-T2DM drug discovery and a promising chemical
probe for GLUT4 associated pathways exploration.
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Introduction
GLUT4 as a member of glucose transporters (Gluts) family
plays a critical role in glucose uptake in several insulin target
tissues, such as muscle and adipose [1,2]. The importance of
GLUT4 for maintaining glucose homeostasis and insulin sensitiv-
ity has been extensively addressed in different animal models [3–
5]. GLUT4 is exquisitely controlled by its translocation or/and
expression in tissue-specific, hormone-regulated, and metabolic
manners [6–10]. The capability of GLUT4 translocation evalu-
ated by its endocytosis and exocytosis ratio is well regulated in
physiological condition [11], and GLUT4 translocation impair-
ment is tightly associated with insulin resistance and elevated of
plasma glucose levels [1,11]. In addition, GLUT4 expression also
exhibits its significance in insulin responsiveness and glucose
tolerance as indicated in GLUT4 deficient or over-expressed mice
model [1].
As reported, dysfunctional glucose uptake in muscle or adipose
contributes largely to the onset of T2DM [12]. Considering the
vital role of GLUT4 in the rate-limit step of glucose transport,
targeting the pathways associated with GLUT4 has thus become
an attractive strategy for drug discovery against T2DM and other
metabolic disorders [13,14]. Recent research has shown that the
agents capable of regulating GLUT4 translocation or expression
may exhibit their potentials for anti-diabetic treatments. Metfor-
min, as a major oral anti-diabetic drug, can efficiently modulate
the insulin-mediated GLUT4 translocation [15]. AICAR, which
improves glucose homeostasis in ob/ob mice, could increase
GLUT4 mRNA/protein expression levels [16,17]. Since induction
of GLUT4 translocation or expression has been proved to be
effective for anti-T2DM therapy, the agents with dual functions in
enhancing both GLUT4 translocation and expression are
expected to exhibit more potent anti-diabetes properties. More-
over, either GLUT4 translocation or expression is involved in
complicated pathways, which are still poorly understood. Dual-
functional agents could be good probes for unraveling such
pathways. Accordingly, we seek to discover the agents that
potently induce both GLUT4 translocation and expression.
Considering that natural products are major resources of
bioactive agents for their large-scale structural diversity, we have
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by the constructed IN Cell 1000 Analyzer based high-content-
screening platform. Finally, we determined the natural product
(+)-Rutamarin (Rut, Fig. 1a) that potently induces both GLUT4
translocation and expression. Rut can efficiently improve insulin
sensitivity and glucose homeostasis in diet-induced obese (DIO)
mice. Further research indicates that Rut takes its effects by acting
on two distinct targets. As a specific inhibitor of protein tyrosine
phosphatase 1B (PTP 1B), it stimulates GLUT4 translocation and
glucose uptake, while as an RXRa agonist Rut enhances GLUT4
expression in 3T3-L1 adipocytes. Moreover, using molecular
modeling and crystallographic approaches, the binding of Rut
against these two targets has been fully investigated at atomic
levels. Our results have thus highlighted the potential for this
natural product as a promising lead compound in anti-T2MD
drug discovery, and as a valuable chemical probe in GLUT4
complicated pathways investigation.
Results
(+)-Rutamarin (Rut) is a dual inducer of both GLUT4
translocation and expression
Based on the lab-constructed IN Cell Analyzer 1000 platform
(see Experimental Procedures) against the in-house natural
product library (,5000 compounds), we have discovered 10
natural products that strongly induce the insulin-stimulated
GLUT4 translocation. Among these compounds, Rut exhibits its
stimulation activity of EC50 at 7.0 mM( Fig. 1b, c). Interestingly,
the enhancement of Rut on the insulin-induced GLUT4
translocation is even stronger than those of compound-2 (C-2), a
known PTP1B selective inhibitor [18], and pervanadate, the
reported general tyrosine phosphatase inhibitor [19] (Fig. 1d). We
also find that Rut significantly induces GLUT4 translocation in
fully differentiated 3T3-L1 adipocytes (Fig. 1e). It is noted that the
displayed GLUT4 is the total cellular GLUT4 in Fig. 1e.A s
described in the experimental procedures, before staining with
fluorescence antibody, 0.2% Triton X-100 is applied to punching
holes in the cell membranes to let antibodies enter cytoplasm. We
also notice that the GLUT4 fluorescence intensity is brighter than
the control fluorescence intensity (Fig. 1e). To study whether
insulin or insulin plus Rut treated 3T3-L1 adipocyte might
increase GLUT4 protein level in a short time, Western blot is
performed. The result shows that GLUT4 protein level keeps no
change within the different treatments (Supplemental Fig. S1a).
As indicated also in Fig. 1e, at basal, GLUT4 vesicles are widely
separated in cytoplasm, after staining with fluorescence antibody,
the whole cell shows similar but weak fluorescence intensity. After
insulin or insulin plus Rut stimulation, GLUT4 vesicles are
aggregated at the cell membrane near to the cell nucleus. From the
above, we conclude that there is no change for the total GLUT4
protein, while the aggregated GLUT4 proteins in different areas
made the different fluorescence intensity. As a result, we think that
this phenomenon is caused by the accumulation of GLUT4
vesicles or probably due to a change in accessibility of the antigen
by the antibody (fixed cells), caused by Rut. In addition, the
insulin-stimulated GLUT4 translocation renders around 1.5-fold
over the basal in IN Cell 1000 analyzer based system. Such a lower
response compared with the published result might be tentatively
resulted from the different systems used [20].
Subsequently, all determined compounds with the ability to
induce GLUT4 translocation are tested for their induction on
GLUT4 expression in 3T3-L1 adipocytes. Among them, only Rut
is found to potently increase GLUT4 protein level (Fig. 1h) and
dose-dependently induce GLUT4 promoter activity (Fig. 1f). In
investigation of the short or long-term effects of Rut in 3T3-L1
adipocytes, we have detected the insulin-induced GLUT4
translocation and glucose uptake in a time-dependent manner.
As indicated, Rut greatly enhances the insulin-induced GLUT4
translocation at 8th hour (Supplemental Fig. S1c and d) and
exhibits no obvious increment on GLUT4 protein level (Supple-
mental Fig. S1e). However, Rut potently increases GLUT4
protein level at 48th hour (Fig. 1h). Therefore, Rut is determined
to be a dual-functional inducer enhancing the insulin-induced
GLUT4 translocation at short term and GLUT4 expression at
long term.
As reported, GLUT4 is primarily expressed in muscle and
adipose tissues [21]. In response to insulin, both GLUT4
translocation from cytoplasm to cell membrane and GLUT4
expression facilitate glucose transport [1]. Since Rut is capable of
inducing both these two processes, it should stimulate the glucose
uptake. As expected, Rut dose-dependently enhances the insulin-
induced glucose uptake, and such an enhancement is much greater
than that of compound-2 (Fig. 1g).
(+)-Rutamarin (Rut) induces GLUT4 translocation as a
PTP1B inhibitor
To address how Rut takes its effect on GLUT4 translocation,
we have investigated the Rut-induced GLUT4-relevant pathways.
In the assay, we first confirm the insulin sensitivity of CHO/
GLUT4 cell line by Western blot, although there has been already
the report on the double stable transfected HEK293 (GLUT4 plus
IRS1) based approach [22]. In our work, the robust insulin-
induced phosphorylation of insulin receptor (IR) or AKT
(Fig. 2a,c) has indicated that our platform is reliable for the
insulin-stimulated GLUT4 translocation assay.
PI3 kinase-AKT/PKB pathway is confirmed to be involved in
the insulin-stimulated GLUT4 translocation [1]. Here we find
that, in the insulin-treated CHO-K1 cells, Rut enhances the
insulin-induced tyrosine phosphorylation of IR and the serine
phosphorylation of AKT in a dose-dependent manner, without
altering the total protein levels of IR and AKT (Fig. 2a). To
further confirm our results in CHO cells, we also use 3T3-L1
adipocytes as a model to study insulin action and glucose
metabolism [20]. As indicated, the insulin-stimulated phosphory-
lation levels of IR and AKT have been largely increased with Rut
treatment in 3T3-L1 adipocytes (Fig. 2b).
Based on the finding that Rut sensitizes insulin signaling, we
next explore the effects of this compound on insulin pathway. As
shown in Fig. 2c, the phosphorylation levels of IR and AKT are
obviously increased in the Rut-treated CHO-K1 cells. Moreover,
Rut also induces basal GLUT4 translocation and glucose uptake
in CHO-K1 and 3T3-L1 adipocytes without insulin induction
(Fig. 2d, e). These results thereby suggest that Rut alone can
activate insulin signaling, although its effect on glucose uptake is
much lower than that of insulin. Therefore, the enhancement of
the insulin-induced GLUT4 translocation by Rut has revealed its
potent activity in insulin-sensitivity improvement.
To investigate whether PI3 kinase-AKT/PKB pathway is
necessary for Rut-induced GLUT4 translocation, the effects of
Rut on GLUT4 translocation is detected in the presence or
absence of the potent PI3 kinase inhibitor wortmannin. As
indicated, wortmannin completely inhibits Rut or insulin-simulat-
ed GLUT4 translocation (Fig. 2f), implying that PI3 kinase-
AKT/PKB pathway is necessary for Rut-induced GLUT4
translocation.
Given that Rut can enhance insulin-stimulated IR phosphor-
ylation and its effect on GLUT4 translocation is abolished by
wortmannin, it is thus proposed that Rut possibly targets the
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According to our knowledge that the protein tyrosine phosphatases
(PTPs) family members can directly dephosphorylate IR thus
negatively regulating insulin signaling [23], the PTPs could be one
of the first candidates for Rut acting target. To test this hypothesis,
the inhibitory activity and selectivity of Rut against PTPs,
including PTP1B, PTPa, TC-PTP, LAR and CD45, have been
determined. The results are listed in Table 1. Rut is determined
to be a PTP1B inhibitor (IC50=6.4 mM, Fig. 3a) and shows good
selectivity on PTP1B over other PTPs family members (Table 1).
Moreover, the Lineweaver-Burk analysis indicates that Rut is a
competitive inhibitor of PTP1B (Fig. 3b).
To further confirm that Rut induces GLUT4 translocation by
inhibiting PTP1B, we test the potential activity of Rut on GLUT4
translocation in the presence or absence of the known PTP1B
general inhibitor pervanadate (Fig. 3c). As indicated, both Rut
and pervanadate induce GLUT4 translocation either with
(Fig. 1d, and Supplementary Fig. S1b) or without insulin
stimulation (Fig. 2e), while Rut cannot enhance the pervanadate-
stimulated GLUT4 translocation, and vice versa (Fig. 3c), this result
Figure 1. (+)-Rutamarin enhances both GLUT4 translocation and expression. (a) Chemical structure of (+)-Rutamarin. (b) Insulin (170 nM)
activates GLUT4 translocation within 5 minutes in CHO-K1/GLUT4 cells that are pre-treated with Rut (20 mM) for 8 hours followed by insulin (170 nM)
stimulation for 5 minutes, with (c)E C 50 value of 7.0 mM. Green fluorescence represents the total GLUT4, and red fluorescence depicts the translocated
GLUT4 to cell membrane. (d) Insulin (170 nM)-induced GLUT4 translocation of CHO-K1/GLUT4 cells treated with compound-2 (C2, 10 mM),
pervanadate (Pervan, 100 mM) and Rut (5, 10, 20 mM) for 5 minutes. (e) Immunofluorescence with antibody against GLUT4 (green), DAPI (blue) in 3T3-
L1 adipocytes. GLUT4 translocation is detected either in the insulin (17 nM) stimulated 3T3-L1 adipocytes for 5 minutes, or pre-treated with Rut
(20 mM) for 8 hours and then stimulated with insulin (17 nM) for 5 minutes. (f) Rut potently stimulates GLUT4 promoter activity in 3T3-L1 adipocytes
(20 mM, Rut was pre-treated in the cells for 24 hours. Reporter gene is GLUT4 promoter-luciferase plasmid together with Renilla luciferase expression
vector as a control). (g)H
3-glucose uptake assay in fully differentiated 3T3-L1 adipocytes treated with C2 (10 mM) and different doses of Rut (5–
25 mM). Treatment of Rut for 30 minutes improves the insulin (17 nM)-stimulated glucose uptake. (h) GLUT4 expression is determined by western
blotting with an antibody against GLUT4 in 3T3-L1 adipocytes treated with Rut (20 mM) for 48 hours. Data are presented as means 6 s.e.m (*P,0.05,
**P,0.01) from three independent experiments.
doi:10.1371/journal.pone.0031811.g001
Figure 2. (+)-Rutamarin activates and sensitizes insulin signaling. Phosphorylations of IR and AKT in insulin (170 nM)-stimulated (a) CHO-K1
cells and (b) insulin (17 nM)-stimulated differentiated 3T3-L1 adipocytes cells for 5 minutes with different doses of Rut determined by western
blotting with antibodies against IR (Tyr1146), AKT (Ser473). (c) Rut (20 mM) 8 h-treatment increases IR and AKT phosphorylations in CHO-K1 cells. (d)
Rut (20 mM) 8 h-treatment promotes GLUT4 translocation in CHO-K1/GLUT4 cells. (e) Treatment of Rut (20 mM) for 8 hours improves glucose uptake
in 3T3-L1 adipocytes without insulin stimulation. (f) Wortmannin (1 mM), inhibitor of PI3 kinase, blocks the Rut (20 mM) or insulin (170 nM)-induced
GLUT4 translocation. Data are presented as means 6 s.e.m (*P,0.05,**P,0.01) from three independent experiments.
doi:10.1371/journal.pone.0031811.g002
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translocation without affecting other pathways.
Therefore, combining the previous results that both pervana-
date and compound-2 increase the insulin-stimulated glucose
uptake similar to Rut (Fig. 1d,g), it is thus suggested that the Rut-
induced GLUT4 translocation is through its inhibition of PTP1B.
(+)-Rutamarin (Rut) stimulates GLUT4 expression as an
RXRa agonist
As demonstrated above, Rut induces GLUT4 promoter activity
thereby enhancing GLUT4 expression, while GLUT4 expression
has been reported to be regulated by nuclear receptor family,
especially PPARc (Peroxisome proliferator-activated receptor c)
[2]. Accordingly, the effects of Rut on a series of nuclear receptors
are determined, including RXRa (Retinoid X receptor a), FXR
(Farnesoid X receptor), LXRa (Liver X receptor a) and PPARc.
The results indicate that Rut is able to dose-dependently enhance
both the activities of RXR-response element (RXRE) and PPAR-
response element (PPRE) (Fig. 4a, b) without influencing the
activities of LXR-response element (LXRE) and FXR-response
element (FXRE) (Fig. 4c, d).
Given that PPARc partners with RXRa to form a ‘‘permissive’’
heterodimer, which can be activated by either RXRa or PPARc
modulator [24], it is possible that Rut increases the transcriptional
activities of both RXRa:RXRa homodimer and PPARc:RXRa
heterodimer by activating RXRa or PPARc. Therefore, we next
test the effects of Rut on the transcriptional activities of RXRa and
PPARc. Firstly, the binding affinity of Rut to the ligand-binding
domain (LBD) of RXRa or PPARc is determined using the
surface plasmon resonance (SPR) technology based Biacore
instrument. The results show that Rut can dose-dependently bind
to RXRa-LBD (Fig. 5a) with equilibrium disassociation constant
(KD) value of 5.08 mM (Supplementary Table S1). However, there
is no binding between Rut and PPARc-LBD (Fig. 5b). As positive
controls, the KD values of 9-cis-retinoic acid (the known RXRa
agonist) to RXRa-LBD and rosiglitazone (the known PPARc
agonist) to PPARc-LBD are determined as 0.66 and 5.82 mM,
respectively (Supplementary Fig. S2a and d, Table S1). RXRa-
LBD or PPARc-LBD is reported to exhibit notably conforma-
tional changes upon agonist binding, subsequently recruiting its
co-activator such as the steroid receptor coinducer-1 (SRC1) [25].
To study whether Rut is able to enhance the interaction between
RXRa-LBD or PPARc-LBD and the co-activator, the binding
affinity of RXRa-LBD or PPARc-LBD against SRC1613–773
containing the LXXLL motifs [26] in the presence of different
concentrations of Rut is measured. As indicated, RXRa-LBD
dose-dependently interacts with SRC1 (KD=1.16 mM, Supple-
mentary Fig. S2b). Similar to 9-cis-retinoic acid (Supplementary
Fig. S2c), Rut efficiently enhances the interaction between
RXRa-LBD and SRC1 (Fig. 5c). However, as shown in
Fig. 5d, Rut cannot enhance the interaction between PPARc-
LBD and SRC1 despite that rosiglitazone greatly enhanced the
interaction between PPARc-LBD and SRC1 (Supplementary
Fig. 2d, e, f). Additionally, the control experiment shows that
Rut does not bind to SRC1 (Fig. 5e).
Subsequently, yeast two-hybrid assay is employed to further
validate the effect of Rut on the co-activator recruitment. The
results clearly show that Rut dose-dependently enhances the
interaction of SRC1 with RXRa (Fig. 5f). Therefore, based on
the SPR and yeast two-hybrid results, we thus conclude that Rut
functions as an RXRa agonist (Fig. 4b).
Considering that RXRa agonist 9-cis-retinoic acid could
modulate GLUT4 promoter activity thereby increasing GLUT
expression [7,10], we then test whether Rut is also able to increase
GLUT4 promoter activity through targeting RXRa. In the assay,
Table 1. Selectivity of compounds against a panel of PTPs.
PTPs IC50 (mM)
(+)-Rutamarin Compound-2 Pervanadate
PTP1B 6.4 5.5 0.015
PTPa NI
* NI
* 0.059
LAR NI
* NI
* 0.026
CD45 .100 NI
* 0.006
TC-PTP 26.8 33.9 0.036
* NI: No inhibition at 100 mM.
doi:10.1371/journal.pone.0031811.t001
Figure 3. (+)-Rutamarin is a PTP1B inhibitor. (a) Rut inhibits the purified PTP1B enzyme activity with IC50 value of 6.4 mM. (b) The double-
reciprocal plots indicates that Rut is a competitive inhibitor of PTP1B determined by Lineweaver-Burk method. (c) Rut (20 mM) enhances the insulin
but not the pervanadate (100 mM)-induced GLUT4 translocation in CHO/GLUT4 cells. Data are presented as means 6 s.e.m (*P,0.05, **P,0.01) from
three independent experiments.
doi:10.1371/journal.pone.0031811.g003
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reduce transcription of these genes (Fig. 6a). In the presence of
rxra siRNA, Rut loses its ability to activate GLUT4 promoter,
compared with the pSuperbasic control vector assay (Fig. 6b).
However, pparc siRNA has no effects on Rut-induced GLUT4
promoter activation (Fig. 6c), while pparc siRNA itself moderately
activated GLUT4 promoter as previously reported [7]. Therefore,
our results thus demonstrate that knockdown of RXRa abolishes
the Rut-induced increase in GLUT4 promoter activity, thereby
suggesting that Rut induces GLUT4 expression by targeting
RXRa.
Binding models of (+)-Rutamarin (Rut) with PTP1B and
RXRa
Since we failed to obtain the crystal of PTP1B-Rut complex,
molecular modeling is thereby performed to investigate the
potential binding mode of Rut to PTP1B at an atomic level
(Fig. 7a). The results suggest that Rut forms a hydrogen bond
with the side chain of Asp48 and interacts with the side chain of
Tyr46 via p-p stacking, and hydrophobically interacts with Arg47,
Asp181, Phe182, Ser215, Ser216, Ala217, Ile219, Gly220, and
Arg221 in PTP1B catalytic site (Fig. 7a). Moreover, the
importance of Asp48 within Rut/PTP1B interaction is further
validated by the reduced inhibitory potency of Rut against the
D48A mutant of PTP1B (Supplementary Fig. S4).
On the other hand, our determined crystal structure of RXRa-
LBD complexed with Rut and SRC1 indicates that Rut binds to
the ligand-binding pocket (LBP) by interacting with the hydro-
phobic residues Val265, Leu309, Ile310, Phe313, Leu325,
Leu326, Val342, Ile345, Phe346, Leu433, His435, Leu436 and
Phe439 (Fig. 7b). Two hydrogen bonds form between the oxygen
atom OAG of Rut and two nitrogen atoms of Arg316. On the
other side of Rut, the oxygen atom OAH also forms one hydrogen
bond with Cys432. Rut is further stabilized by the water-mediated
hydrogen bonds with Leu309 and Arg316. Superposition of Rut-
bound RXRa-LBD with 9-cis-retinoic acid-bound structure [27]
shows perfect overlapping of these two agonists, thus revealing
their potential similar agonistic mechanisms (Fig. 7c). Arg316 is
found to play an essential role by forming identical hydrogen
bonds with the oxygen atoms from both 9-cis-retinoic acid and
Rut. In the current structure, Rut also activates RXRa by
overturning the C-terminal helix 12, consequently recruiting the
co-activator SRC1. All these observations have supported that Rut
functions as an RXRa agonist, in consistent with the pertinent cell
and tissue based assays.
Figure 4. (+)-Rutamarin selectively activates RXRa:RXRa and PPARc:RXRa transcriptional activities. HEK293 cells are transiently
transfected by Lipo2000 respectively with RXRa, PPARc, FXR, and LXRa plasmids plus pGL3-RXRE luciferase vector and renilla luciferase vector for
5 hours. Cells are then incubated with indicated concentrations of compounds for another 24 h and finally lysed. Luciferase activities are measured
using Dual Luciferase Assay System kit. Rut dose-dependently activates (a) RXRa:RXRa and (b) PPARc:RXRa activities. Rut has no effects on (c) FXR:
RXRa and (d) LXRa:RXRa activities. Data are presented as means 6 s.e.m (*P,0.05, **P,0.01) from three independent experiments.
doi:10.1371/journal.pone.0031811.g004
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31811Figure 5. (+)-Rutamarin functions as an RXRa agonist. In SPR technology based Biacore experiment, the purified RXRa-LBD and PPARc-LBD
proteins are immobilized on M5 chips. Rut dose-dependently binds to (a) RXRa-LBD but renders no affinity to (b) PPARc-LBD. (c) Rut promotes RXRa-
LBD/SRC1613–773 interaction. (d) Rut has few effects on PPARc-LBD/SRC1613–773 interaction (e) Rut has no obvious binding affinity to SRC1613–773.( f)
Rut dose-dependently enhances the interaction of RXRa with SRC1 in yeast two-hybrid assay. Data are presented as means 6 s.e.m (*P,0.05,
**P,0.01) from three independent experiments.
doi:10.1371/journal.pone.0031811.g005
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insulin sensitivity in diet-induced obese (DIO) mice
The in vivo anti-hyperglycemic effects of Rut are investigated
against DIO mice. In the assay, C57BL mice are fed with either
regular chow diet or high-fat diet (HFD) for 3 months, and Rut
(10 mg/kg), vehicle or metformin (200 mg/kg, as a positive
control) are subsequently administered by intraperitoneal (IP)
injection for 2 months (Fig. 8a). Food consumption is not
significantly different between the Rut and vehicle-treated mice.
The body weights of Rut and vehicle-treated mice slightly decrease
in the first four weeks, and become stable in the last four weeks,
which may be caused by mice in-adaption of compounds
administration at the first 4 weeks. No other significant abnormal
animal responses are found with Rut administration, and there is
no overt toxicity in the body organs such as liver, kidney, spleen
and heart, and no distinct difference in the weights of these organs
between Rut-treated and control groups (Supplementary Fig.
S3c).
As indicated in Fig. 8b, Rut could efficiently increase the
mRNA levels of PPARc:RXRa-regulated genes in epididymis fat
tissues, including pepck, GLUT4 and adiponectin [7,28,29], which
suggests the potential Rut-involved activation of PPARc:RXRa
heterodimer in vivo. Additionally, Rut also increases GLUT4
expression in epididymis fat tissues (Fig. 8c). In addition, the
fasting plasma glucose of Rut-treated DIO mice is significantly
lower than the control obese group, while no obvious difference is
observed between Rut and vehicle-treated lean mice (Fig. 8d). For
investigation of the potential acute effect of Rut on mice, Rut
(2 mg/kg) is subsequently administered by intraperitoneal (IP)
injection for 2 weeks, and we find that Rut could efficiently
improve fasting plasma glucose level and insulin receptor (IR)
phosphorylation (Supplemental Fig. S1f, g).
To further explore the effects of Rut on glucose homeostasis,
glucose tolerance test (GTT) is employed. As shown in Fig. 8e,
fasting plasma glucose is much lower after glucose challenge in
Rut-treated DIO mice compared with the vehicle-treated group
(Fig. 8e), while Rut and vehicle-treated lean mice exhibit similar
profiles in glucose clearance over time (Fig. 8f). Furthermore, the
improvement of insulin sensitivity by Rut is also evaluated by
insulin tolerance test (ITT). As indicated in Fig. 8g with the
percentage of basal glucose level, Rut-treated DIO mice eliminate
glucose at a faster rate compared with the vehicle-treated group,
while there is no obvious difference between Rut and vehicle-
treated lean mice (Fig. 8h).
In addition, it is tentatively suggested that the large dose of
metformin (200 mg/kg) has made the similar ability in decrease of
the fasting plasma glucose level to Rut (Fig. 8g). As published, the
anti-hyperglycemic effect of metformin was due to the suppression
of lipid oxidation and hepatic glucose production [30].
Discussion
Although the detailed pathogenic mechanisms of diabetes are
still elusive, impaired insulin signaling and dys-regulated gene
expression have been investigated in this disease [12]. GLUT4
plays its crucial role in the rate-limiting step for cells to utilize
glucose by both of its translocation and expression [1]. Inducers of
GLUT4 translocation or expression were found to exert their
beneficial effects on sensitizing insulin signal and recovering the
dys-regulated gene expressions, eventually resulting in ameliora-
tion of metabolic syndrome [15–17]. Specific dual-inducers of
both GLUT4 translocation and expression could be thus expected
to become more potent for metabolic syndrome treatment. To
date, targeting GLUT4 translocation, varied methods have been
Figure 6. (+)-Rutamarin increases GLUT4 promoter activity through RXRa. (a) Knockdown plasmid pSuper-RXRa or pSuper-PPARc is
transiently transfected into HEK293 cells by Lipo2000 for 5 hours, and the knockdown efficiency is determined by western bloting with antibody
against RXRa or PPARc.( b) In the presence of rxra siRNA, Rut (20 mM) loses its ability to activate GLUT4 promoter, while similar activation of the
promoter is found when pSuperbasic control vector is co-transfected. (c) pparc siRNA has no effects on the activation of GLUT4 promoter by Rut
(20 mM). Data are presented as means 6 s.e.m (*P,0.05,**P,0.01) from three independent experiments.
doi:10.1371/journal.pone.0031811.g006
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meet the high throughput compound screening [20,22,31]. In the
current work, we have constructed the IN Cell Analyzer 1000
based screening platform to discover the dual inducers of both
GLUT4 translocation and expression. We finally determine that
the natural product (+)-Rutamarin functions as this dual inducer
(Fig. 1). It could largely enhance the insulin-stimulated glucose
uptake in 3T3-L1 adipocytes as a potent insulin sensitizer
(Fig. 1h). The in vivo study further indicates that Rut efficiently
increases GLUT4 expression in epididymis fat tissues and
improves glucose homeostasis and insulin sensitivity in DIO mice
(Fig. 8).
Target inspection has demonstrated that targeting PTP1B is
responsible for Rut stimulating GLUT4 translocation, while Rut
promotes GLUT4 expression by functioning as an RXRa
agonist. Enzymatic assay suggested that Rut is a competitive
inhibitor of PTP1B (Fig. 3). Molecular modeling and site-
directed mutagenesis further confirm that Rut binds to the
substrate pocket of PTP1B (Fig. 7a and Supplementary Fig.
S4). PTP1B has been proved to be a validated target against
diabetes [32], and antisense oligonucleotides of PTP1B has
already entered phase II clinical trials [33]. Since PTPs share
highly structural conservation, selectivity and bioavailability
restrictions have challenged the development of small inhibitors
against PTP1B. Here Rut has been determined to exhibit good
selectivity against PTP1B over other PTPs family members,
highlighting its valuable potential in the discovery of drug lead
compound against diabetes.
As reported, broad spectrum inhibitors of PTPs like vanadate
and pervanadate, induce GLUT4 translocation by a mechanism
independent of PI3-kinase, as indicated by the fact that the known
PI3-kinase inhibitor wortmannin does not inhibit the pervanadate-
stimulated glucose uptake [34]. Interestingly, our work demon-
strates that Rut could efficiently stimulate PI3-kinase pathway, and
wortmannin completely inhibits Rut or insulin-stimulated GLUT4
translocation (Fig. 2f), these results thus demonstrate that PI3
kinase-AKT/PKB pathway is necessary for the Rut-induced
GLUT4 translocation. Compared with C2, a non-competitive
inhibitor of PTP1B [18], Rut functions as a competitive PTP1B
inhibitor and potently increases the insulin-stimulated phosphor-
ylation levels of IR and AKT. In addition, the greater effects of
Rut over pervandate and C2 might be tentatively ascribed to their
different PTP-1B inhibition modes and the potential wortmannin-
sensitive related pathways for Rut.
RXRa interacts with different nuclear receptors to form
heterodimers, thus executing different functions [2]. The pleio-
tropic roles of RXRa have made this nuclear receptor an
attractive target for drug discovery. To date, some RXRa
modulators have been reported to exhibit glucose-lowering,
insulin-sensitizing or anti-obesity effects [35]. Here, Rut is
determined as a heterodimer-selective agonist. It activates
PPARc:RXRa but exhibits no effects on LXRa:RXRa or
FXR:RXRa dimerization. Such a PPARc:RXRa heterodimeric
selectivity for Rut is expected to benefit its potential in drug
development [8]. Different from rosiglitazone and pioglitazone,
the two members of thiazolidinedione (TZD) PPARc agonists with
Figure 7. Binding models of (+)-Rutamarin with PTP1B and RXRa. (a) The interactions between Rut and the residues in PTP1B substrate-
binding site. (b) The interactions between Rut and RXRa determined by the crystal structure of RXRa-LBD complexed with Rut. (RXRa is shown as
ribbon. All the residues interacting with Rut are shown as sticks. Hydrogen bonds are shown in yellow dot line.) (c) Superposition of Rut (yellow) with
9-cis-retinoic acid (green) in the ligand-binding pocket, and hydrogen bonds form for these two compounds with residue of Arg316.
doi:10.1371/journal.pone.0031811.g007
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expression via enhancing RXRa-LBD/SRC1 interaction and
PPARc:RXRa heterodimer transcriptional activity through direct
binding to RXRa.
The anti-hyperglycemic effect of Rut has been investigated in
DIO mice, and the greatly elevated expression of PPARc:RXRa
in Rut-treated group could be clearly determined (Fig. 8b). In
addition, our results demonstrate that the glucose homeostasis is
improved in Rut-treated DIO mice as indicated by the decreased
fasting plasma glucose and enhanced glucose clearance rate in
GTT assay (Fig. 8g, e). Moreover, Rut efficiently meliorates
insulin sensitivity in 3T3-L1 adipocytes, and the insulin sensitivity
of the Rut-treated animals is also statistically improved. Since
GLUT4 is the principal glucose transporter responsible for glucose
disposal, the Rut-induced increament of both GLUT4 transloca-
tion and expression may account for the improved glucose
homeostasis in DIO mice, while the inhibition of PTP1B of Rut
could benefit the improved in vivo insulin sensitivity. In addition,
the fact that Rut functions as an RXRa agonist and selectively
activates PPARc:RXRa heterodimer may also be contributed to
its anti-hyperglycemic and insulin-sensitizing effects [37,38].
In conclusion, we have identified the natural product Rut as the
first reported dual inducer of both GLUT4 translocation and
expression, which can efficiently improve glucose homeostasis and
insulin sensitivity in DIO mice. Further target exploration research
indicates that Rut functions as both a specific PTP1B inhibitor and
an RXRa agonist that selectively activates PPARc:RXRa
heterodimer. Our results have implied that Rut could serve as
not only a promising lead compound for further anti-T2DM drug
discovery, but also a valuable chemical probe for new GLUT4-
associated pathways investigation.
Materials and Methods
Materials
All cell culture reagents are purchased from GIBCO and all
BIAcore agents are from GE Healthcare. Insulin (cellular assay),
wortmannin, penicillin-streptomycin, biotin, p-nitrophenyl-b-D-
galactopyranoside (PNP-b-Gal), cytochalasin B, p-nitrophenyl
phosphate (pNPP), D-glucose and Ca-pantochenate are purchased
from Sigma-Aldrich. Alexa Fluor647 goat anti-mouse IgG is
purchased from Molecular Probes (Invitrogen). All antibodies for
western blot are from Cell Signaling Technology except anti-
GAPDH antibody (KangChen, China), anti-myc antibody (Tian-
gen Biotech, China) and anti-GLUT4 antibody (Santa Cruz). BCA
Protein Assay Kit is purchased from Beyotime (China). The
Clontech MATCHMAKER Two-Hybrid System is a generous gift
from Prof. Y. Gong (Shanghai Institutes for Biological Sciences,
CAS, China). Dual Luciferase Assay System is purchased from
Promega. 2-[
3H]-deoxy-D-glucose is from Perkinelmer. Insulin (IP
injection) is from HumulinH, Lily. High fat diet (D12492i) is
purchased from Research Diets Inc. TRIzol reagent is from
Generay Biotech, China. PrimeScript
TM RT reagent Kit is
obtained from TaKaRa, Japan. SYBR Green Real time PCR
master mix is from TOYOBO, Japan. (+)-Rutamarin (Rut) is
synthesized as described [39].
Plasmids
pEGFPN1-GLUT4-myc vector is cloned from pCXN2-IRGT-
myc (kindly provided by Dr. Yousuke Ebina, University of
Tokushima, Japan.) with XhoI-BamHIs i t e s ,a n dp G L 3 - G L U T 4 - p r o
was described previously [40]. pGBKT7-RXRa-LBD223–463 and
pGADT7-SRC1613–773 were cloned using human cDNA as
templates with EcoRI-PstIa n dEcoRI-BamHI sites, respectively.
pSuperbasic-PPARc and pSuperbasic-RXRa vectors were con-
structed by inserting the coding sequences of siRNA [41,42] into the
pSuperbasic with BglII-HindIII sites. The sequences were
GCCCTTCACTACTGTTGAC (PPARc) and GCACTATG-
GAGTGTACAGC (RXRa). pcDNA3.1-PPARc, pcDNA3.1-
RXRa, pSV-PPRE-Luc were described previously [43]. pCMX-
FXRplasmidisagiftfromStefanK.Westin(X-CeptorTherapeutics
Inc., CA). pGL3-pro-RXRE-Luc vector is constructed by inserting 4
DR1 sequences with XhoI-BglII sites. The vector pGL3-pro-FXRE-
Luc is kindly provided by Dr. Majlis Hermansson (AstraZeneca,
Mo ¨lndal, Sweden), and LXRE vector is a generous gift from Prof.
CharisseS.Vales (The Medicine Instituteat Universityof California,
CA). The plasmid pET15b-PPARc-LBD202–477 is kindly donated by
Dr. J. Uppenberg (Department of Structural Chemistry, Pharmacia
and Upjohn, Sweden). The plasmid pET15b-SRC1613–773 is
constructed with NdeI-BamHI sites, and pET22b-RXRa-LBD223–463
with NdeI-XhoI site, while pGEX4T-1-TC-PTP1–288, and pGEX4T-
1-PTP1B1–321 with BamHI-HindIII and BamHI-EcoRI sites respec-
tively using a PTP1B or TC45 vector as template that are kindly
provided by Prof. Nicholas K. Tonks (Cold Spring Harbor
Laboratory, NY). Vectors pGEX2T-LAR1282–1888 and pGEX2T-
CD45560–1256 are kindly donated by Prof. Rafael Pulido (Centro de
Investigacio ´n Prı ´ncipe Felipe, Spain), pGEX2T-PTPa182–803 is by
Prof. Frank R. Jirik (University of British Columbia, Canada), and
pET15b-hRXRa-LBD is by Dr. William Bourguet (Centre de
Biochimie Structurale, France).
Site-directed mutagenesis
The plasmid pGEX4T1-PTP1B (D48A) is generated by site-
directed mutagenesiswithpGEX4T1-PTP1B(WT) astemplate.The
primerpairsaresense:59-accgaaataggtacagagccgtcagtccctttgaccatag-
39 and antisense: 59-ctatggtcaaagggactgacggctctgtacctatttcggt-39.
Protein purification
The plasmids pGEX2T-PTPa, pGEX4T-TC-PTP, pGEX2T-
LAR, pGEX2T-CD45, pGEX4T-PTP1B, pET15b-SRC1, pET15b-
hPPARc-LBD, and pET15b-RXRa-LBD are transformed into BL21
Figure 8. (+)-Rutamarin efficiently improves glucose homeostasis and insulin sensitivity in diet-induced obese (DIO) mice. (a)
Scheme of C57/BL6 DIO male mice model and compound administration (HFD, high-fat diet; FPG, fasting plasma glucose; OGTT, oral glucose
tolerance test; ITT, insulin tolerance test). Vehicle, Rut (10 mg/kg) or metformin (200 mg/kg) is administered daily by intraperitoneal (IP) injection for 8
weeks. (b) Rut (10 mg/kg) efficiently increases the mRNA levels of PPARc:RXRa-regulated genes, including pepck, GLUT4 and adiponectin in
epididymis fat tissues (n=7 for each group). CHD (chow diet), HFD (high-fat diet). (c) Rut increases GLUT4 expression in epididymis fat tissues (n=7
for each group). L and H stand for low (2 mg/kg) and high dose (10 mg/kg) of Rut, respectively. (d) Rut (10 mg/kg) decreases the fasting plasma
glucose (n=7 for each group) after 8-week administration. (e) Rut (10 mg/kg) improves glucose disposal rate (n=7 for each group). The oral glucose
tolerance tests indicate the time course of glucose excursion following oral administration of glucose (2 g/kg) in vehicle and Rut (10 mg/kg) treated
DIO mice (n=7 for each group). (Vehicle-V, Rut-R, Metformin-M). (f) Rut (10 mg/kg) has no effects on glucose disposal rate in control lean mice (n=7
for each group). Rut (10 mg/kg) increases insulin sensitivity in DIO mice (n=7 for each group). (g) Insulin tolerance tests are performed in mice from
each group (vehicle, 10 mg/ml Rut). Lines indicate the time courses of glucose levels after IP injection of insulin (1 U/kg). (h) Rut (10 mg/kg) has no
effects on insulin sensitivity in control lean mice (n=7 for each group). (& for vehicle-treated group, m for Rut-treated group, and . for metformin-
treated group). Data are presented as means 6 s.e.m (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0031811.g008
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4 h induction with isopropyl-b-D-thiogalactopyranoside (0.5 mM,
IPTG) at suitable temperature (22uC for GST-TC-PTP, GST-CD45,
37uC for GST-PTP1B, 25uC for PTPa, LAR, PPARc,R X R a and
SRC1613–773), the cell cultures are collected and frozen at 280uC.
Purifications of GST-tagged proteins (GST-PTP1B, GST-TC-PTP,
and GST-CD45) are carried out according to the manufacturer’s
instructions (Amersham Pharmacia), while purification of His-tagged
proteins, including SRC1, PPARc-LBD, and RXRa-LBD are
processed based on the manufacturer’s instructions (Novagen).
Cell culture and differentiation
CHO-K1 and CHO-K1/GLUT4 cells are cultured in F-12 Ham
medium supplemented with 10% FBS, penicillin-streptomycin
(50 U/ml). HEK293 cells are cultured in Delbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS, and 3T3-
L1 adipocytes were cultured in DMEM supplemented with 10%
FBS, penicillin-streptomycin, biotin (3.2 mM) and Ca-pantochenate
(16.8 mM). All cells are cultured at 37uC in humidified atmosphere
with 5% CO2, and the differentiation procedure of 3T3-L1 followed
the classic method [44]. Briefly, two days after 100% confluence,
cells are stimulated with MDI stimulus (0.5 mM Methylisobutyl-
xanthine, 1 mM Dexamthasone and 170 nM insulin) for 3 days, and
then cells are stimulated with 170 nM insulin for another 3-day.
Construction of CHO-K1/GLUT4 stable cell lines
CHO-K1 cells are transfected with pEGFPN1-GLUT4-myc
plasmid using Lipofectamine 2000, and subsequently screened
with G418 (800 mg/ml). The CHO-K1/GLUT4 stable cell line is
obtained by picking up clones.
Quantification of GLUT4 translocation ratio
CHO-K1/GLUT4 cells are seeded into 96-well plate. After
cells reached 100% confluence, F12 medium is changed to 3T3-
L1 medium and incubated for 2 days [45]. 8-hour serum
starvation later, cells are stimulated with insulin for 5 minutes,
fixed with 3.7% formaldehyde for 15 minutes, and labeled with
anti-myc monoclonal antibody and secondary antibody (Alexa
Fluor 647 conjuncted anti-mouse antibody). Fluorescence pictures
were obtained by IN Cell Analyzer 1000 Instrument (GE
Healthcare) with the same exposure time. The basic unit
comprises several core components including a Nikon microscope
and a high-resolution CCD camera. Membrane-located GLUT4
is represented by the intensity of red fluorescence (Alex fluor 647)
and normalized by the intensity of green fluorescence (GLUT4-
EGFP), which is assigned to the total GLUT4 [46].
For GLUT4 translocation assay in 3T3-L1 adipocytes, the cells
are fully differentiated (the 10th day after MDI stimulation), and
seeded onto 24-well plates. After cultured in serum-free medium
for 8 h, cells are incubated with Rut for 2 h and insulin for
10 min, and then rinsed with PBS, fixed with 4% formaldehyde
for 10 min, and permeated with 0.2% Triton X-100 in PBS for
10 min. Cells are subsequently washed with PBS and 3% bovine
serum albumin for 20 min, and sequentially incubated with
primary antibody (Abcam GLUT4 antibody) for 1 h and
secondary antibody (Alexa Fluor 488 conjuncted anti-mouse
antibody) for another 1 h. Finally, the glass-slips are washed with
PBS for examination using OLYMPUS FV-1000 confocal
microscope. All pictures are made in the same time experiment.
Western blot
Insulin sensitizing effects of Rut are investigated in CHO-K1
and 3T3-L1 adipocytes. After incubation with compounds in
serum-free medium for indicated time, cells are stimulated with
insulin (170 nM for CHO-K1 cells and 17 nM for 3T3-L1
adipocytes) for 5 min, and the stimulation is stopped by ice-cold
PBS. The effect of Rut on insulin signaling is also investigated in
CHO-K1 cells. In the assay, cells are stimulated with Rut (20 mM,
8 h) or insulin (170 nM, 5 min), and then lysed on ice. GLUT4
protein level is studied in the differentiated 3T3-L1 adipocytes (the
10th day after MDI stimulation). After incubation of compounds
for 48 h, cells are lysed on ice. The proteins are resolved by SDS-
polyacrylamide gel electrophoresis and electro-transferred to
polyvinylidene difluoride membranes. The membrane is blocked
by 5% skimmed milk and incubated with antibodies. Proteins are
visualized by the ECL detecting system.
2-Deoxyglucose uptake in 3T3-L1 adipocytes
3T3-L1 adipocytes are fully differentiated (the 10th day after
MDI stimulation) and seeded into 24-well plate. After incubation
with compounds in serum-free medium containing 0.5% BSA for
8 hours, medium is changed to Krebs buffer containing 17 M
insulin and incubated for 30 minutes. In the last 5 minutes, cells
are incubated with 2-[
3H]-deoxy-D-glucose. The glucose uptake is
stopped by ice-cold PBS, and the cells are then lysed with 0.1%
Triton. Finally the radioactivity is calculated by a scintillation
counter. Cytochalasin B is used to measure nonspecific uptake,
and the value is subtracted from all the data. Radioactivity is
normalized by total protein concentration that is measured by
BCA kit.
PTP1B enzyme inhibition assay
The enzymatic activities of the recombinant PTPs are measured
at 25uC using pNPP as substrate. The initial velocities of enzymatic
reactions are determined by continuously measuring the absor-
bance at 405 nm every 15 s using a microplate spectrophotometer
(Bio-Rad). To evaluate IC50 values, PTPs (0.3 mM) are incubated
with compounds in reaction buffer (50 mM HEPES, pH 7.0,
1 mM EDTA, and 100 mM NaCl) for 10 min and the reactions
are initiated by addition of pNPP (5 mM). To determine the
inhibition type, each concentration of Rut (0, 50 and 75 mM) is
incubated with PTP1B (0.3 mM) in reaction buffer (50 mM
HEPES, pH7.0, 1 mM EDTA, and 100 mM NaCl) for 10 min
and the reactions are initiated by different concentrations of pNPP
(0.5–10 mM). The inhibition type is determined using double-
reciprocal plots. In determination of the selectivity of Rut against
PTPs, the result is referred as no inhibition when 100 mM Rut
inhibits no enzyme activity. The same reaction systems are
designed for all PTPs including PTP1B.
Surface plasmon resonance (SPR) technology based
assay
Binding affinities of Rut towards proteins are analyzed using
SPR technology based Biacore 3000 instrument (GE Healthcare).
In the assay, proteins are immobilized to CM5 chips using a
standard amine-coupling procedure (Biacore manual). The
proteins to be covalently bound to the chips are diluted in
10 mM sodium acetate buffer (pH4.5) to a final concentration of
0.10 mg/ml. Before experiments, baseline is equilibrated with a
continuous flow of running buffer (10 mM HEPES, 150 mM
NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant P20, pH7.4) for
2 hours. Subsequently, Rut with a gradient of concentrations is
injected to the channels at a flow rate of 20 mL/min for
60 seconds, followed by disassociation for 120 seconds. The 1:1
Langmuir binding fitting model in BIAevaluation software version
3.1 (Biacore) is used to determine the equilibrium dissociation
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purified SRC1613–773 is immobilized to a CM5 chip. Different
concentrations of PPARc-LBD or RXRa-LBD are injected to the
channel at a flow rate of 20 mL/min for 60 s, followed by
disassociation for 120 s. To further detect the effects of Rut on
PPARc-LBD/SRC1 or RXRa-LBD/SRC1 interactions, 1 mM
PPARc-LBD or RXRa-LBD is incubated with Rut (16.8–
100 mM) for 1 hour, and then injected onto the chip.
Transient transfection assay
HEK293 cells are transfected with luciferase reporter plus
Renilla luciferase vector and other plasmids if needed for 5 hours,
and cells are then incubated with indicated concentrations of
compounds for another 24 h. Finally cells are lysed and luciferase
activities are measured using Dual Luciferase Assay System kit.
The results are presented as the fold activation relative to
untreated cells after normalization with Renilla luciferase values.
Each experiment is repeated at least twice, with each sample
analyzed in triplicates.
Yeast two-hybrid assay
AH109 strain is co-transfected with pGBKT7-RXRa-LBD and
pGADT7-SRC1613–773. Cells are incubated with Rut or 9-cis-
retinoic acid (the known RXRa agonist) for 48 hours, and a-
galactosidase activity is measured as previous report [43].
Tissue RNA extraction and real-time PCR
Four mice in each group are employed for the determination of
gene expression. The total RNA is extracted from epididymis fat
tissues (75 mg/mice) with TRIzol reagent, and the cDNA is
synthesized using PrimeScript
TM RT reagent Kit. Real-time PCR
is performed using SYBR Green Real time PCR master mix on
DNA Engine Opticon 2 System. The PCR cycle is 94uC for
20 seconds, 60uC for 30 seconds and 72uC for 30 seconds. The
primer pairs for the related genes are described in Supplementary
Table S2.
Diet-induced obesity (DIO) mice model and compound
administration
All animals receive humane care, and the experimental
procedures are performed according to the institutional ethical
guidelines on animal care. C57/BL6 male mice are obtained from
Shanghai SLAC Laboratory Animal Co. Ltd, and maintained
under the temperature controlled at 25uC with a 12 h light-dark
cycle. Eight-week-old male mice are fed regular chow or high fat
diet (HFD, D12492i, from Research Diets Inc.) for 12 weeks. The
DIO mice and normal lean mice are grouped randomly, and each
group contains 7 mice. Vehicle, Rut (10 mg/kg) or metformin
(200 mg/kg) is administered daily by intraperitoneal (IP) injection
for 8 weeks. Individual body weight and fasting plasma glucose are
measured weekly. Averaged daily food intake is measured twice a
week. At the termination of the study, mice are dissected, and the
weight of tissues (liver, kidney, spleen, heart, perirenal fat, and
epididymis fat) is determined.
The epididymis fat is lysed and the supernatant is separated by
SDS-PAGE and transferred to polyvinylidene difluoride mem-
branes (Millipore). Membranes are incubated in blocking buffer
(BB) containing 5% skimmed milk with 0.5% Tween 20 in Tris-
buffered saline and immunoblotted with the related antibodies
overnight at 4uC in BB. After incubation, membranes are washed
and incubated with horseradish peroxidase-labeled secondary
antibodies (Amersham), and then the proteins are detected by
SuperSignal West Pico chemiluminescent substrate (Pierce).
Oral glucose tolerance test (OGTT) and insulin tolerance
test (ITT)
Male mice treated with compounds for 8 weeks are used for oral
glucose tolerance test. After 6 h fasting, plasma glucose levels are
measured and glucose (2 g/kg) is loaded. Blood samples are taken
from the tail vein at different time points (0, 30, 90, and 120 min).
In insulin tolerance tests, after 6 h fasting, plasma glucose levels
are measured and insulin (1 U/kg) is administered by IP injection.
Blood samples are taken at indicated time points (0, 15, 30, 45, 60,
90, and 120 min). Blood glucose levels are measured by ACCU-
CHEK Active blood sugar testmeter (Roche). Statistical evaluation
is performed via two-way ANOVA. Significant difference at
P,0.05: *, P,0.01: **.
Molecular Modeling
Structure-based analysis against PTP1B is performed using the
advanced docking program AUTODOCK 4.0 [47,48] (PDB code:
1AAX) [49]. In the first step, a grid box is generated with
70670670 points altogether to encompass the whole ligand
binding site. The spacing parameter is set to 0.375 A ˚. The affinity
and electrostatic potential maps are calculated for each type of
atom present in the ligand structure. Then the Lamarckian genetic
algorithm (LGA) is applied to deal with the protein-ligand
interactions by a newly revised scoring function that includes
terms of Van der Waals, hydrogen bond, de-solvation energy,
torsional free energy and unbound system’s energy. The step size is
set to 0.2 A ˚ for translation and 5u for orientation and torsion. The
numbers of generation, energy evaluation, and docking runs are
set to 500,000, 2,500,000 and 20, respectively. Finally, the
evaluation with the lowest binding energy is used to analyze
ligand pose. The interaction model of ligand/PTP1B is produced
using the Molecular Operating Environment (MOE) program
(Chemical Computing Group, Montreal, Canada) based on the
docked complex structure, and the docking approach comprises
the in silico modeling.
Crystallization and structure determination
The crystal of RXRa-LBD complexed with Rut and SRC1
peptide (KHKILHRLLQDSS) grows in 8% v/v Tacsimate
pH8.0, 20% (w/v) PEG3350 at 4uC. Diffraction data is collected
on the BL17U at Shanghai Synchrotron Radiation Facility (China)
and processed with HKL2000 [50]. Phases for the structure are
initially determined with Molrep and refined with Refmac5 to a
resolution of 2.0 A ˚ in the CCP4 suite [51]. Model building is
performed manually with COOT [52]. The quality of the final
model is checked with PROCHECK [53]. The coordinate has
been deposited to the Protein Data Bank with accession numbers
of 3PCU. All structural figures are prepared with PyMol [54]. The
statistics of the data collection and structure refinement are
summarized in Supplementary Table S3.
Calculations
Data are expressed as means 6 s.e.m (*P,0.05,**P,0.01).
Statistical analysis is conducted using Student’s t test or one-way
ANOVA. OGTT and ITT data are conducted using two-way
ANOVA.
Supporting Information
Figure S1 Dose-dependent induction of GLUT4 translo-
cation by insulin and short-term effects of Rut. (a)
GLUT4 protein level is detected either in the insulin (17 nM)
stimulated 3T3-L1 adipocytes for 5 minutes, or pre-treated with
Rut (20 mM) for 8 hours and then stimulated with insulin (17 nM)
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stimulated with indicated concentrations of insulin (5 min) or
pervanadate (30 min). Subsequently membrane GLUT4 is
determined and EC50 values of insulin and pervandate are fitted
to 100 nM and 51 mM, respectively. (c, d) Effect of rut on insulin
induced GLUT4 translocation and glucose uptake in time-
dependent manner. (e) GLUT4 expression is determined by
western blotting with an antibody against GLUT4 in 3T3-L1
adipocytes treated with Rut (20 mM) in time-dependent manner.
(f) Rut (2 mg/kg) improves plasma glucose level in DIO mice
(n=7 for each group) for 2 weeks. (g) Insulin receptor
phosphorylation level is detected in Rut-treated mice epididymis
fat tissues.
(TIF)
Figure S2 RXRa agonist 9-cis-retinoic acid (9-cis-RA) or
PPARc agonist rosglizitone (Ros) dose-dependently
enhances interaction between RXRa-LBD and SRC1 or
between PPARc-LBD and SRC1. (a) RXRa agonist 9-cis-RA
or (d) PPARc agonist rosglizitone (Ros) dose-dependently binds to
RXRa-LBD and PPARc-LBD, respectively. (b) RXRa-LBD or
(e) PPARc-LBD dose-dependently binds to SRC1. (c)9 - cis-RA
and (f) rosglizitone enhances interaction between RXRa-LBD or
PPARc-LBD and SRC1.
(TIF)
Figure S3 The effects of (+)-rutamarin administration.
(a) diet, (b) body weight and (c) main organ weights in DIO
mice,average daily food intake is measured twice a week and
individual body weight is measured weekly. At the termination of
the study, mice are dissected, and tissue weights (Liver, kidney,
spleen, heart, perirenal fat, and epididymis fat) are determined.
(TIF)
Figure S4 Binding activity of (+)-Rutamarin with PTP1B
(WT) and PTP1B (D48A). Rut inhibits PTP1B (WT) and
PTP1B (D48A) activity with IC50 value of 6.4 and 14.8 mM,
respectively.
(TIF)
Table S1 Association (kon) and Dissociation (koff) Rate
and Equilibrium Dissociation (KD) Constants of (+)-
rutamarin binding to RXRa-LBD obtained from SPR
experiments.
(TIF)
Table S2 The Primers in Real-time PCR.
(TIF)
Table S3 Data collection and structure refinement
statistics.
(TIF)
Author Contributions
Conceived and designed the experiments: XS HJ LH. Performed the
experiments: YZ HZ X-gY HS JC CL LC MZ. Analyzed the data: YZ HZ
X-gY HS JC CL LC MZ JY. Contributed reagents/materials/analysis
tools: YZ HZ X-gY HS JC CL LC MZ. Wrote the paper: YZ HZ X-gY
XS HJ.
References
1. Bryant NJ, Govers R, James DE (2002) Regulated Transport of the Glucose
Transporter Glut4. Nat Rev Mol Cell Biol 3: 267–277.
2. Armoni M, Harel C, Karnieli E (2007) Transcriptional regulation of the GLUT4
gene: from PPAR-c and FOXO1 to FFA and inflammation. Trends in
Endocrinology & Metabolism 18: 100–107.
3. Gibbs EM, Stock JL, McCoid SC, Stukenbrok HA, Pessin JE, et al. (1995)
Glycemic Improvement in Diabetic dbldb Mice by Overexpression of the
Human Insulin-regulatable Glucose Transporter (GLUT4). J Clin Invest 95:
1512–1518.
4. Zisman A, Peroni OD, Abel ED, Michael MD, Mauvais-Jarvis F, et al. (2000)
Targeted disruption of the glucose transporter 4 selectively in muscle causes
insulin resistance and glucose intolerance. Nat Med 6: 924–928.
5. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, et al. (2001) Adipose-selective
targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature
409: 729–733.
6. Sleeman MW, Zhou H, Rogers S, Ng KW, Best JD (1995) Retinoic acid
stimulates glucose transporter expression in L6 muscle cells. Mol Cell Endocrinol
108: 161–167.
7. Armoni M, Kritz N, Harel C, Bar-Yoseph F, Chen H, et al. (2003) Peroxisome
Proliferator-activated Receptor-c Represses GLUT4 Promoter Activity in
Primary Adipocytes, and Rosiglitazone Alleviates This Effect. J Biol Chem
278: 30614–30623.
8. Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI (2003) Expression
of the Insulin-responsive Glucose Transporter GLUT4 in Adipocytes Is
Dependent on Liver X Receptor a. J Biol Chem 278: 48283–48291.
9. Zorzano A, Palacin M, Guma A (2005) Mechanisms regulating GLUT4 glucose
transporter expression and glucose transport in skeletal muscle. Acta Physiol
Scand 183: 43–58.
10. Montessuit C, Papageorgiou I, Campos L, Lerch R (2006) Retinoic acids
increase expression of GLUT4 in dedifferentiated and hypertrophied cardiac
myocytes. Basic Res Cardiol 101: 27–35.
11. Hou JC, Pessin JE (2007) Ins (endocytosis) and outs (exocytosis) of GLUT4
trafficking. Curr Opin Cell Biol 19: 466–473.
12. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet
365: 1415–1428.
13. Saltiel AR, Kahn CR (2001) Insulin signaling and the regulation of glucose and
lipid metabolism. Nature 414: 799–806.
14. Shulman AI, Mangelsdorf DJ (2005) Retinoid X Receptor Heterodimers in the
Metabolic Syndrome. N Engl J Med 353: 604–615.
15. Lee JO, Lee SK, Jung JH, Kim JH, You GY, Kim SJ, et al. (2010) Metformin
induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal
muscle cells. J Cell Physiol 226: 974–981.
16. Buhl ES, Jessen N, Schmitz O, Pedersen SB, Pedersen O, et al. (2001) Chronic
Treatment With 5-Aminoimidazole-4-Carboxamide-1-_-D-Ribofuranoside
Increases Insulin-Stimulated Glucose Uptake and GLUT4 Translocation in
Rat Skeletal Muscles in a Fiber Type–Specific Manner. Diabetes 50: 12–17.
17. Leick L, Fentz J, Bienso RS, Knudsen JG, Jeppesen J, et al. (2010) PGC-1a is
required for AICAR-induced expression of GLUT4 and mitochondrial proteins
in mouse skeletal muscle. Am J Physiol Endocrinol Metab 299: E456–465.
18. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, et al. (2004) Allosteric
inhibition of protein tyrosine phosphatase 1B. Nature structural & molecular
biology 11: 730–737.
19. Huyer G, Liu S, Kelly J, Moffat J, Payette P, et al. (1997) Mechanism of
Inhibition of Protein-tyrosine Phosphatases by Vanadate and Pervanadate. J Biol
Chem 272: 843–851.
20. Kohn AD (1996) Expression of a Constitutively Active Akt Ser/Thr Kinase in
3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4
Translocation. TheJournal of Biological Chemistry 271: 31372–31378.
21. Olson AL, Pessin JE (1996) Structure,Function,and Regulation of the
Mammalian Facilitative Glucose Transporter Gene Family. Annu Rev Nutr
16: 235–256.
22. Liu F, Dallas-Yang Q, Castriota G, Fischer P, Santini F, et al. (2009)
Development of a novel GLUT4 translocation assay for identifying potential
novel therapeutic targets for insulin sensitization. The Biochemical journal 418:
413–420.
23. Stoker AW (2005) Protein tyrosine phosphatases and signalling. J Endocrinol
185: 19–33.
24. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106–1118.
25. Xu L, Glass CK, Rosenfeld MG (1999) Coactivator and corepressor complexs in
nuclear receptor function. Curr Opin Genet Dev 9: 140–147.
26. Needham M, Raines S, McPheat J, Stacey C, Ellston J, et al. (2000) Differential
interaction of steroid hormone receptors with LXXLL motifs in SRC-1a
depends on residues flanking the motif. J Steroid Biochem Mol Biol 72: 35–46.
27. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, et al. (2000) Crystal
structure of the human RXRa ligand-binding domain bound to its natural
ligand: 9-cis retinoic acid. Embo J 19: 2592–2601.
28. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM (1995) PPAR gamma 2
regulates adipose expression of the phosphoenolpyruvate carboxykinase gene.
Mol Cell Biol 15: 351–357.
29. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, et al. (2002) Induction
of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARc
Agonists: A Potential Mechanism of Insulin Sensitization. Endocrinology 143:
998–1007.
30. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, et al. (2000) Mechanism
by Which Metformin Reduces Glucose Production in Type 2 Diabetes. Diabetes
49: 2063–2069.
31. Wang Q (1998) GLUT4 translocation by insulin in intact muscle cells: detection
by a fast and quantitative assay. FEBS Letters 427: 193–197.
(+)-Rutamarin as a Dual Inducer of GLUT4
PLoS ONE | www.plosone.org 14 February 2012 | Volume 7 | Issue 2 | e3181132. Zhang S, Zhang ZY (2007) PTP1B as a drug target: recent developments in
PTP1B inhibitor discovery. Drug Discov Today 12: 373–381.
33. Liu G (2004) Review Technology evaluation: ISIS-113715 (Isis). Curr Opin Mol
Ther 6: 331–336.
34. Tsiani E, Bogdanovic E, Sorisky A, Nagy L, Fantus IG (1998) Tyrosine
Phosphatase Inhibitors, Vanadate and P ervanadate, Stimulate Glucose
Transport and GLUT Translocation in Muscle Cells by a Mechanism
Independent of Phosphatidylinositol 3-Kinase and Protein Kinase C. Diabetes
47: 1676–1686.
35. Pinaire JA, Reifel-Miller A (2007) Therapeutic Potential of Retinoid X Receptor
Modulators for the Treatment of theMetabolic Syndrome. PPAR Res 2007:
94156.
36. Willson TM, Lambert MH, Kliewer SA (2001) Peroxisome Proliferator-
Activated Receptor c and Metabolic Disease. Annu Rev Biochem 70: 341–367.
37. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, et al. (2001)
Metabolic Effects of Rexinoids: Tissue-Specific Regulation of Lipoprotein Lipase
Activity. Mol Pharmacol 59: 170–176.
38. Picard F, Auwerx J (2002) PPARc and Glucose Homeostasis. Annu Rev Nutr
22: 167–197.
39. Zhang YN, Zhang SL, Ma L, Zhang Y, Shen X, et al. (2008) Total Synthesis of
(+)-Rutamarin. Advanced Synthesis & Catalysis 350: 2373–2379.
40. Shen H, Zhang Y, Ding H, Wang X, Chen L, et al. (2008) Farnesoid X receptor
induces GLUT4 expression through FXR response element in the GLUT4
promoter. Cell Physiol Biochem 22: 1–14.
41. Cao X, Liu W, Lin F, Li H, Kolluri SK, et al. (2004) Retinoid X Receptor
Regulates Nur77/Thyroid Hormone Receptor 3-Dependent Apoptosis by
Modulating Its Nuclear Export and Mitochondrial Targeting. Mol Cell Biol
24: 9705–9725.
42. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, et al. (2005) Suppression of
prostate tumor cell growth by stromal cell prostaglandin D synthase-derived
products. Cancer Res 65: 6189–6198.
43. Ye F, Zhang ZS, Luo HB, Shen JH, Chen KX, et al. (2006) The Dipeptide H-
Trp-Glu-OH Shows Highly Antagonistic Activity against PPARc: Bioassay with
Molecular Modeling Simulation. Chembiochem 7: 74–82.
44. Frost SC, Lane MD (1985) Evidence for the Involvement of Vicinal Sulfhydryl
Groups in Insulinactivated Hexose Transport by 3T3-Ll Adipocytes. J Biol
Chem 260: 2646–2652.
45. Bogan JS, McKee AE, Lodish HF (2001) Insulin-Responsive Compartments
Containing GLUT4 in 3T3-L1 and CHO Cells: Regulation by Amino Acid
Concentrations. Mol Cell Biol 21: 4785–4806.
46. Lampson MA, Racz A, Cushman SW, McGraw TE (2000) Demonstration of
insulin-responsive trafficking of GLUT4 and vpTR in fibroblasts. J Cell Sci 113:
4065–4076.
47. Morris GM, Goodsell DS, Huey R, Olson AJ (1996) Distributed automated
docking of flexible ligands to proteins: parallel applications of AutoDock 2.4.
J Comput Aided Mol Des 10: 293–304.
48. Huey R, Morris GM, Olson AJ, Goodsell DS (2007) A semiempirical free energy
force field with charge-based desolvation. J Comput Chem 28: 1145–1152.
49. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, et al. (1997)
Identification of a second aryl phosphate-binding site in protein-tyrosine
phosphatase 1B: a paradigm for inhibitor design. Proc Natl Acad Sci U S A
94: 13420–13425.
50. Otwinowski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected
in Oscillation Mode. In: CW. Carter Jr., RM. Sweet, eds. (1997). Methods in
Enzymology Macromolecular Crystallography. pp 307–326.
51. Navaza J (1994) AMoRe: an automated package for molecular replacement.
Acta Crystallogr D Biol Crystallogr 50: 760–763.
52. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
53. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK:
a program to check the stereochemical quality of protein structures. J App Cryst
26: 283–291.
54. DeLano WL( 2002 ) http://www.pymol.org Accessed 2011 Jul 3.
(+)-Rutamarin as a Dual Inducer of GLUT4
PLoS ONE | www.plosone.org 15 February 2012 | Volume 7 | Issue 2 | e31811